Vaccinex Inc (VCNX)

[conix]

VCNX INVESTMENT HIGHLIGHTS:

*Recent $40 million Initial Public Offering led by: Oppenheimer, Ladenburg and BTIG

*Lead Program(VX15) is humanized monoclonal antibody that binds to and blocks unique target - Semaphorin 4D(SEMA4D)

*1st Lead trial(Phase II) will have a readout at ASCO in June(NSCLC trial) after enrollment complete in May 2019 - partner Merck KGaA

*2nd Combo Phase 1/2 melanoma Trial in combo with nivolumab - partnership with Bristol Myers Squibb

*Anti-SEMA4D Antibody enhances Activity of Immune Checkpoint Inhibitors
*Huntington's Disease(HD) - neurodegenerative disease caused by mutation in a single gene - symptoms appear between ages 30 to 50

*No currently approved treatments to alter the course of Huntington's Disease - Vaccinex program granted Orphan Drug and Fast Track by FDA

*Very experienced Management team and Board of Directors

Vaccinex - Company Background:

Vaccinex, Inc. (Nasdaq: VCNX) is a publicly-traded clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases with unmet medical needs, including neurodegenerative diseases, cancer and autoimmune disorders.


Market Capitalization: $75 million
Range - 52 week: $12.00 - $3.32
Current Price: $5.50
Trades on: Nasdaq NASDAQ
Ticker Symbol: VCNX

Website: www.vaccinex.com